nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—SRC—pancreatic cancer	0.17	0.516	CbGaD
Ponatinib—KDR—pancreatic cancer	0.16	0.484	CbGaD
Ponatinib—FLT3—Erlotinib—pancreatic cancer	0.0503	0.119	CbGbCtD
Ponatinib—FGFR1—Sunitinib—pancreatic cancer	0.0384	0.0907	CbGbCtD
Ponatinib—FGFR2—Sunitinib—pancreatic cancer	0.0384	0.0907	CbGbCtD
Ponatinib—FLT3—Sunitinib—pancreatic cancer	0.0331	0.0783	CbGbCtD
Ponatinib—RET—Sunitinib—pancreatic cancer	0.0331	0.0783	CbGbCtD
Ponatinib—KDR—Sunitinib—pancreatic cancer	0.0331	0.0783	CbGbCtD
Ponatinib—ABL1—Erlotinib—pancreatic cancer	0.0289	0.0683	CbGbCtD
Ponatinib—KIT—Sunitinib—pancreatic cancer	0.0263	0.0622	CbGbCtD
Ponatinib—PDGFRA—Sunitinib—pancreatic cancer	0.0263	0.0622	CbGbCtD
Ponatinib—ABCB11—Tamoxifen—pancreatic cancer	0.0163	0.0386	CbGbCtD
Ponatinib—RET—enteric nervous system—pancreatic cancer	0.00923	0.267	CbGeAlD
Ponatinib—ABCG2—Tamoxifen—pancreatic cancer	0.00776	0.0183	CbGbCtD
Ponatinib—ABCB11—Doxorubicin—pancreatic cancer	0.00685	0.0162	CbGbCtD
Ponatinib—ABCG2—Erlotinib—pancreatic cancer	0.0066	0.0156	CbGbCtD
Ponatinib—ABCB11—bile duct—pancreatic cancer	0.00616	0.178	CbGeAlD
Ponatinib—ABCG2—Irinotecan—pancreatic cancer	0.00596	0.0141	CbGbCtD
Ponatinib—ABCG2—Fluorouracil—pancreatic cancer	0.00572	0.0135	CbGbCtD
Ponatinib—ABCB11—bile—pancreatic cancer	0.00474	0.137	CbGeAlD
Ponatinib—ABCG2—Docetaxel—pancreatic cancer	0.00437	0.0103	CbGbCtD
Ponatinib—ABCG2—Sunitinib—pancreatic cancer	0.00435	0.0103	CbGbCtD
Ponatinib—CYP3A5—Tamoxifen—pancreatic cancer	0.0043	0.0102	CbGbCtD
Ponatinib—CYP2C8—Tamoxifen—pancreatic cancer	0.00414	0.00977	CbGbCtD
Ponatinib—CYP3A5—Erlotinib—pancreatic cancer	0.00366	0.00864	CbGbCtD
Ponatinib—CYP2C8—Erlotinib—pancreatic cancer	0.00352	0.00831	CbGbCtD
Ponatinib—CYP3A5—Irinotecan—pancreatic cancer	0.0033	0.00781	CbGbCtD
Ponatinib—ABCG2—Doxorubicin—pancreatic cancer	0.00326	0.0077	CbGbCtD
Ponatinib—CYP2C8—Fluorouracil—pancreatic cancer	0.00305	0.0072	CbGbCtD
Ponatinib—ABCB1—Tamoxifen—pancreatic cancer	0.0028	0.00662	CbGbCtD
Ponatinib—CYP2D6—Tamoxifen—pancreatic cancer	0.00264	0.00623	CbGbCtD
Ponatinib—KDR—umbilical vein—pancreatic cancer	0.00244	0.0704	CbGeAlD
Ponatinib—CYP3A5—Docetaxel—pancreatic cancer	0.00242	0.00572	CbGbCtD
Ponatinib—ABCB1—Gemcitabine—pancreatic cancer	0.00241	0.0057	CbGbCtD
Ponatinib—CYP3A5—Sunitinib—pancreatic cancer	0.00241	0.00569	CbGbCtD
Ponatinib—ABCB1—Erlotinib—pancreatic cancer	0.00238	0.00563	CbGbCtD
Ponatinib—CYP2D6—Erlotinib—pancreatic cancer	0.00224	0.0053	CbGbCtD
Ponatinib—ABCB1—Irinotecan—pancreatic cancer	0.00215	0.00508	CbGbCtD
Ponatinib—CYP3A4—Tamoxifen—pancreatic cancer	0.00168	0.00396	CbGbCtD
Ponatinib—ABCB1—Docetaxel—pancreatic cancer	0.00158	0.00372	CbGbCtD
Ponatinib—ABCB1—Sunitinib—pancreatic cancer	0.00157	0.00371	CbGbCtD
Ponatinib—CYP3A4—Erlotinib—pancreatic cancer	0.00143	0.00337	CbGbCtD
Ponatinib—CYP3A4—Irinotecan—pancreatic cancer	0.00129	0.00304	CbGbCtD
Ponatinib—ABCB1—Doxorubicin—pancreatic cancer	0.00117	0.00278	CbGbCtD
Ponatinib—FGFR4—digestive system—pancreatic cancer	0.00113	0.0325	CbGeAlD
Ponatinib—PDGFRA—gall bladder—pancreatic cancer	0.00111	0.0321	CbGeAlD
Ponatinib—BCR—islet of Langerhans—pancreatic cancer	0.00111	0.032	CbGeAlD
Ponatinib—CYP2D6—Doxorubicin—pancreatic cancer	0.00111	0.00261	CbGbCtD
Ponatinib—CYP3A4—Docetaxel—pancreatic cancer	0.000944	0.00223	CbGbCtD
Ponatinib—CYP3A4—Sunitinib—pancreatic cancer	0.000939	0.00222	CbGbCtD
Ponatinib—KIT—gall bladder—pancreatic cancer	0.000888	0.0256	CbGeAlD
Ponatinib—ABL1—Topotecan—Irinotecan—pancreatic cancer	0.00078	0.424	CbGdCrCtD
Ponatinib—SRC—islet of Langerhans—pancreatic cancer	0.000714	0.0206	CbGeAlD
Ponatinib—CYP3A4—Doxorubicin—pancreatic cancer	0.000704	0.00166	CbGbCtD
Ponatinib—TEK—pancreas—pancreatic cancer	0.000565	0.0163	CbGeAlD
Ponatinib—RET—digestive system—pancreatic cancer	0.00053	0.0153	CbGeAlD
Ponatinib—ABCB11—digestive system—pancreatic cancer	0.000517	0.0149	CbGeAlD
Ponatinib—ABL1—islet of Langerhans—pancreatic cancer	0.000507	0.0146	CbGeAlD
Ponatinib—FGFR2—digestive system—pancreatic cancer	0.000503	0.0145	CbGeAlD
Ponatinib—SRC—pancreas—pancreatic cancer	0.000502	0.0145	CbGeAlD
Ponatinib—PDGFRA—digestive system—pancreatic cancer	0.000437	0.0126	CbGeAlD
Ponatinib—SRC—digestive system—pancreatic cancer	0.000429	0.0124	CbGeAlD
Ponatinib—KIT—pancreas—pancreatic cancer	0.000409	0.0118	CbGeAlD
Ponatinib—KDR—digestive system—pancreatic cancer	0.000394	0.0114	CbGeAlD
Ponatinib—ABL1—pancreas—pancreatic cancer	0.000356	0.0103	CbGeAlD
Ponatinib—KIT—digestive system—pancreatic cancer	0.000349	0.0101	CbGeAlD
Ponatinib—ABL1—digestive system—pancreatic cancer	0.000304	0.00879	CbGeAlD
Ponatinib—CYP3A5—islet of Langerhans—pancreatic cancer	0.000297	0.00857	CbGeAlD
Ponatinib—CYP3A5—pancreas—pancreatic cancer	0.000209	0.00602	CbGeAlD
Ponatinib—ABL1—Idarubicin—Epirubicin—pancreatic cancer	0.000183	0.0997	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Epirubicin—pancreatic cancer	0.000183	0.0997	CbGdCrCtD
Ponatinib—ABL1—Doxorubicin—Epirubicin—pancreatic cancer	0.000183	0.0997	CbGdCrCtD
Ponatinib—CYP3A5—digestive system—pancreatic cancer	0.000178	0.00514	CbGeAlD
Ponatinib—ABL1—Idarubicin—Doxorubicin—pancreatic cancer	0.00017	0.0923	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Doxorubicin—pancreatic cancer	0.00017	0.0923	CbGdCrCtD
Ponatinib—ABL1—Epirubicin—Doxorubicin—pancreatic cancer	0.00017	0.0923	CbGdCrCtD
Ponatinib—ABCB1—islet of Langerhans—pancreatic cancer	0.000158	0.00455	CbGeAlD
Ponatinib—CYP3A4—digestive system—pancreatic cancer	0.000134	0.00386	CbGeAlD
Ponatinib—CYP2D6—digestive system—pancreatic cancer	0.000132	0.0038	CbGeAlD
Ponatinib—ABCB1—pancreas—pancreatic cancer	0.000111	0.0032	CbGeAlD
Ponatinib—ABCB1—digestive system—pancreatic cancer	9.46e-05	0.00273	CbGeAlD
Ponatinib—Pruritus—Sunitinib—pancreatic cancer	4.65e-05	0.000417	CcSEcCtD
Ponatinib—Breast disorder—Epirubicin—pancreatic cancer	4.64e-05	0.000416	CcSEcCtD
Ponatinib—Constipation—Irinotecan—pancreatic cancer	4.63e-05	0.000415	CcSEcCtD
Ponatinib—Pain—Irinotecan—pancreatic cancer	4.63e-05	0.000415	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	4.62e-05	0.000415	CcSEcCtD
Ponatinib—Dyspnoea—Fluorouracil—pancreatic cancer	4.62e-05	0.000415	CcSEcCtD
Ponatinib—Mental disorder—Docetaxel—pancreatic cancer	4.61e-05	0.000414	CcSEcCtD
Ponatinib—Nasopharyngitis—Epirubicin—pancreatic cancer	4.59e-05	0.000412	CcSEcCtD
Ponatinib—Face oedema—Doxorubicin—pancreatic cancer	4.58e-05	0.000412	CcSEcCtD
Ponatinib—Erythema—Docetaxel—pancreatic cancer	4.58e-05	0.000411	CcSEcCtD
Ponatinib—Malnutrition—Docetaxel—pancreatic cancer	4.58e-05	0.000411	CcSEcCtD
Ponatinib—Decreased appetite—Gemcitabine—pancreatic cancer	4.58e-05	0.000411	CcSEcCtD
Ponatinib—Dyspepsia—Fluorouracil—pancreatic cancer	4.56e-05	0.00041	CcSEcCtD
Ponatinib—Nausea—Tamoxifen—pancreatic cancer	4.55e-05	0.000409	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	4.55e-05	0.000409	CcSEcCtD
Ponatinib—Fatigue—Gemcitabine—pancreatic cancer	4.54e-05	0.000408	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	4.53e-05	0.000406	CcSEcCtD
Ponatinib—Constipation—Gemcitabine—pancreatic cancer	4.51e-05	0.000405	CcSEcCtD
Ponatinib—Pain—Gemcitabine—pancreatic cancer	4.51e-05	0.000405	CcSEcCtD
Ponatinib—Nausea—Erlotinib—pancreatic cancer	4.51e-05	0.000405	CcSEcCtD
Ponatinib—Decreased appetite—Fluorouracil—pancreatic cancer	4.5e-05	0.000404	CcSEcCtD
Ponatinib—Diarrhoea—Sunitinib—pancreatic cancer	4.49e-05	0.000404	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	4.47e-05	0.000402	CcSEcCtD
Ponatinib—Abdominal distension—Epirubicin—pancreatic cancer	4.46e-05	0.000401	CcSEcCtD
Ponatinib—Blood creatinine increased—Doxorubicin—pancreatic cancer	4.45e-05	0.000399	CcSEcCtD
Ponatinib—Back pain—Docetaxel—pancreatic cancer	4.43e-05	0.000398	CcSEcCtD
Ponatinib—Pain—Fluorouracil—pancreatic cancer	4.43e-05	0.000398	CcSEcCtD
Ponatinib—Gastrointestinal pain—Irinotecan—pancreatic cancer	4.42e-05	0.000397	CcSEcCtD
Ponatinib—Dehydration—Doxorubicin—pancreatic cancer	4.42e-05	0.000397	CcSEcCtD
Ponatinib—Muscle spasms—Docetaxel—pancreatic cancer	4.4e-05	0.000396	CcSEcCtD
Ponatinib—Dry skin—Doxorubicin—pancreatic cancer	4.35e-05	0.000391	CcSEcCtD
Ponatinib—Pancreatitis—Epirubicin—pancreatic cancer	4.35e-05	0.000391	CcSEcCtD
Ponatinib—Dizziness—Sunitinib—pancreatic cancer	4.34e-05	0.00039	CcSEcCtD
Ponatinib—Hypokalaemia—Doxorubicin—pancreatic cancer	4.32e-05	0.000388	CcSEcCtD
Ponatinib—Angina pectoris—Epirubicin—pancreatic cancer	4.32e-05	0.000388	CcSEcCtD
Ponatinib—Breast disorder—Doxorubicin—pancreatic cancer	4.29e-05	0.000385	CcSEcCtD
Ponatinib—Abdominal pain—Irinotecan—pancreatic cancer	4.28e-05	0.000384	CcSEcCtD
Ponatinib—Body temperature increased—Irinotecan—pancreatic cancer	4.28e-05	0.000384	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	4.28e-05	0.000384	CcSEcCtD
Ponatinib—Nasopharyngitis—Doxorubicin—pancreatic cancer	4.25e-05	0.000381	CcSEcCtD
Ponatinib—Anaemia—Docetaxel—pancreatic cancer	4.23e-05	0.00038	CcSEcCtD
Ponatinib—Pancytopenia—Epirubicin—pancreatic cancer	4.21e-05	0.000378	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	4.19e-05	0.000376	CcSEcCtD
Ponatinib—Vomiting—Sunitinib—pancreatic cancer	4.17e-05	0.000375	CcSEcCtD
Ponatinib—Body temperature increased—Gemcitabine—pancreatic cancer	4.16e-05	0.000374	CcSEcCtD
Ponatinib—Neutropenia—Epirubicin—pancreatic cancer	4.15e-05	0.000372	CcSEcCtD
Ponatinib—Rash—Sunitinib—pancreatic cancer	4.14e-05	0.000372	CcSEcCtD
Ponatinib—Dermatitis—Sunitinib—pancreatic cancer	4.14e-05	0.000372	CcSEcCtD
Ponatinib—Abdominal distension—Doxorubicin—pancreatic cancer	4.13e-05	0.000371	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Epirubicin—pancreatic cancer	4.12e-05	0.00037	CcSEcCtD
Ponatinib—Headache—Sunitinib—pancreatic cancer	4.11e-05	0.000369	CcSEcCtD
Ponatinib—Leukopenia—Docetaxel—pancreatic cancer	4.1e-05	0.000368	CcSEcCtD
Ponatinib—Body temperature increased—Fluorouracil—pancreatic cancer	4.09e-05	0.000368	CcSEcCtD
Ponatinib—Pancreatitis—Doxorubicin—pancreatic cancer	4.02e-05	0.000361	CcSEcCtD
Ponatinib—Weight decreased—Epirubicin—pancreatic cancer	4.01e-05	0.00036	CcSEcCtD
Ponatinib—Hyperglycaemia—Epirubicin—pancreatic cancer	4e-05	0.000359	CcSEcCtD
Ponatinib—Cough—Docetaxel—pancreatic cancer	4e-05	0.000359	CcSEcCtD
Ponatinib—Angina pectoris—Doxorubicin—pancreatic cancer	4e-05	0.000359	CcSEcCtD
Ponatinib—Pneumonia—Epirubicin—pancreatic cancer	3.98e-05	0.000357	CcSEcCtD
Ponatinib—Hypertension—Docetaxel—pancreatic cancer	3.96e-05	0.000355	CcSEcCtD
Ponatinib—Infestation—Epirubicin—pancreatic cancer	3.95e-05	0.000355	CcSEcCtD
Ponatinib—Infestation NOS—Epirubicin—pancreatic cancer	3.95e-05	0.000355	CcSEcCtD
Ponatinib—Myalgia—Docetaxel—pancreatic cancer	3.9e-05	0.00035	CcSEcCtD
Ponatinib—Arthralgia—Docetaxel—pancreatic cancer	3.9e-05	0.00035	CcSEcCtD
Ponatinib—Nausea—Sunitinib—pancreatic cancer	3.9e-05	0.00035	CcSEcCtD
Ponatinib—Pancytopenia—Doxorubicin—pancreatic cancer	3.9e-05	0.00035	CcSEcCtD
Ponatinib—Asthenia—Irinotecan—pancreatic cancer	3.88e-05	0.000349	CcSEcCtD
Ponatinib—Neuropathy peripheral—Epirubicin—pancreatic cancer	3.88e-05	0.000348	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	3.87e-05	0.000348	CcSEcCtD
Ponatinib—Jaundice—Epirubicin—pancreatic cancer	3.85e-05	0.000346	CcSEcCtD
Ponatinib—Stomatitis—Epirubicin—pancreatic cancer	3.85e-05	0.000346	CcSEcCtD
Ponatinib—Urinary tract infection—Epirubicin—pancreatic cancer	3.84e-05	0.000345	CcSEcCtD
Ponatinib—Neutropenia—Doxorubicin—pancreatic cancer	3.84e-05	0.000345	CcSEcCtD
Ponatinib—Dry mouth—Docetaxel—pancreatic cancer	3.81e-05	0.000343	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	3.81e-05	0.000343	CcSEcCtD
Ponatinib—Asthenia—Gemcitabine—pancreatic cancer	3.78e-05	0.00034	CcSEcCtD
Ponatinib—Hepatobiliary disease—Epirubicin—pancreatic cancer	3.74e-05	0.000336	CcSEcCtD
Ponatinib—Oedema—Docetaxel—pancreatic cancer	3.74e-05	0.000336	CcSEcCtD
Ponatinib—Epistaxis—Epirubicin—pancreatic cancer	3.73e-05	0.000335	CcSEcCtD
Ponatinib—Pruritus—Gemcitabine—pancreatic cancer	3.73e-05	0.000335	CcSEcCtD
Ponatinib—Infection—Docetaxel—pancreatic cancer	3.71e-05	0.000334	CcSEcCtD
Ponatinib—Weight decreased—Doxorubicin—pancreatic cancer	3.71e-05	0.000333	CcSEcCtD
Ponatinib—Hyperglycaemia—Doxorubicin—pancreatic cancer	3.7e-05	0.000332	CcSEcCtD
Ponatinib—Diarrhoea—Irinotecan—pancreatic cancer	3.7e-05	0.000332	CcSEcCtD
Ponatinib—Pneumonia—Doxorubicin—pancreatic cancer	3.68e-05	0.000331	CcSEcCtD
Ponatinib—Nervous system disorder—Docetaxel—pancreatic cancer	3.67e-05	0.000329	CcSEcCtD
Ponatinib—Pruritus—Fluorouracil—pancreatic cancer	3.66e-05	0.000329	CcSEcCtD
Ponatinib—Thrombocytopenia—Docetaxel—pancreatic cancer	3.66e-05	0.000329	CcSEcCtD
Ponatinib—Infestation NOS—Doxorubicin—pancreatic cancer	3.66e-05	0.000329	CcSEcCtD
Ponatinib—Infestation—Doxorubicin—pancreatic cancer	3.66e-05	0.000329	CcSEcCtD
Ponatinib—Skin disorder—Docetaxel—pancreatic cancer	3.63e-05	0.000326	CcSEcCtD
Ponatinib—Diarrhoea—Gemcitabine—pancreatic cancer	3.6e-05	0.000324	CcSEcCtD
Ponatinib—Neuropathy peripheral—Doxorubicin—pancreatic cancer	3.59e-05	0.000322	CcSEcCtD
Ponatinib—Dizziness—Irinotecan—pancreatic cancer	3.58e-05	0.000321	CcSEcCtD
Ponatinib—Haemoglobin—Epirubicin—pancreatic cancer	3.57e-05	0.00032	CcSEcCtD
Ponatinib—Jaundice—Doxorubicin—pancreatic cancer	3.57e-05	0.00032	CcSEcCtD
Ponatinib—Stomatitis—Doxorubicin—pancreatic cancer	3.57e-05	0.00032	CcSEcCtD
Ponatinib—Urinary tract infection—Doxorubicin—pancreatic cancer	3.56e-05	0.000319	CcSEcCtD
Ponatinib—Haemorrhage—Epirubicin—pancreatic cancer	3.55e-05	0.000319	CcSEcCtD
Ponatinib—Diarrhoea—Fluorouracil—pancreatic cancer	3.54e-05	0.000318	CcSEcCtD
Ponatinib—Hypoaesthesia—Epirubicin—pancreatic cancer	3.53e-05	0.000317	CcSEcCtD
Ponatinib—Oedema peripheral—Epirubicin—pancreatic cancer	3.5e-05	0.000314	CcSEcCtD
Ponatinib—Connective tissue disorder—Epirubicin—pancreatic cancer	3.49e-05	0.000313	CcSEcCtD
Ponatinib—Hepatobiliary disease—Doxorubicin—pancreatic cancer	3.46e-05	0.000311	CcSEcCtD
Ponatinib—Epistaxis—Doxorubicin—pancreatic cancer	3.45e-05	0.00031	CcSEcCtD
Ponatinib—Vomiting—Irinotecan—pancreatic cancer	3.44e-05	0.000309	CcSEcCtD
Ponatinib—Dizziness—Fluorouracil—pancreatic cancer	3.43e-05	0.000308	CcSEcCtD
Ponatinib—Visual impairment—Epirubicin—pancreatic cancer	3.42e-05	0.000307	CcSEcCtD
Ponatinib—Rash—Irinotecan—pancreatic cancer	3.41e-05	0.000306	CcSEcCtD
Ponatinib—Dermatitis—Irinotecan—pancreatic cancer	3.41e-05	0.000306	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	3.41e-05	0.000306	CcSEcCtD
Ponatinib—Headache—Irinotecan—pancreatic cancer	3.39e-05	0.000304	CcSEcCtD
Ponatinib—Insomnia—Docetaxel—pancreatic cancer	3.38e-05	0.000304	CcSEcCtD
Ponatinib—Paraesthesia—Docetaxel—pancreatic cancer	3.36e-05	0.000302	CcSEcCtD
Ponatinib—Vomiting—Gemcitabine—pancreatic cancer	3.35e-05	0.000301	CcSEcCtD
Ponatinib—Dyspnoea—Docetaxel—pancreatic cancer	3.33e-05	0.000299	CcSEcCtD
Ponatinib—Rash—Gemcitabine—pancreatic cancer	3.32e-05	0.000298	CcSEcCtD
Ponatinib—Dermatitis—Gemcitabine—pancreatic cancer	3.32e-05	0.000298	CcSEcCtD
Ponatinib—Eye disorder—Epirubicin—pancreatic cancer	3.32e-05	0.000298	CcSEcCtD
Ponatinib—Haemoglobin—Doxorubicin—pancreatic cancer	3.3e-05	0.000297	CcSEcCtD
Ponatinib—Headache—Gemcitabine—pancreatic cancer	3.3e-05	0.000296	CcSEcCtD
Ponatinib—Cardiac disorder—Epirubicin—pancreatic cancer	3.29e-05	0.000296	CcSEcCtD
Ponatinib—Flushing—Epirubicin—pancreatic cancer	3.29e-05	0.000296	CcSEcCtD
Ponatinib—Vomiting—Fluorouracil—pancreatic cancer	3.29e-05	0.000296	CcSEcCtD
Ponatinib—Dyspepsia—Docetaxel—pancreatic cancer	3.29e-05	0.000296	CcSEcCtD
Ponatinib—Haemorrhage—Doxorubicin—pancreatic cancer	3.28e-05	0.000295	CcSEcCtD
Ponatinib—Hypoaesthesia—Doxorubicin—pancreatic cancer	3.27e-05	0.000294	CcSEcCtD
Ponatinib—Rash—Fluorouracil—pancreatic cancer	3.27e-05	0.000293	CcSEcCtD
Ponatinib—Dermatitis—Fluorouracil—pancreatic cancer	3.26e-05	0.000293	CcSEcCtD
Ponatinib—Decreased appetite—Docetaxel—pancreatic cancer	3.25e-05	0.000292	CcSEcCtD
Ponatinib—Headache—Fluorouracil—pancreatic cancer	3.25e-05	0.000291	CcSEcCtD
Ponatinib—Oedema peripheral—Doxorubicin—pancreatic cancer	3.24e-05	0.000291	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Docetaxel—pancreatic cancer	3.23e-05	0.00029	CcSEcCtD
Ponatinib—Connective tissue disorder—Doxorubicin—pancreatic cancer	3.23e-05	0.00029	CcSEcCtD
Ponatinib—Fatigue—Docetaxel—pancreatic cancer	3.22e-05	0.00029	CcSEcCtD
Ponatinib—Angiopathy—Epirubicin—pancreatic cancer	3.22e-05	0.000289	CcSEcCtD
Ponatinib—Nausea—Irinotecan—pancreatic cancer	3.21e-05	0.000289	CcSEcCtD
Ponatinib—Mediastinal disorder—Epirubicin—pancreatic cancer	3.2e-05	0.000287	CcSEcCtD
Ponatinib—Constipation—Docetaxel—pancreatic cancer	3.2e-05	0.000287	CcSEcCtD
Ponatinib—Pain—Docetaxel—pancreatic cancer	3.2e-05	0.000287	CcSEcCtD
Ponatinib—Chills—Epirubicin—pancreatic cancer	3.18e-05	0.000286	CcSEcCtD
Ponatinib—Arrhythmia—Epirubicin—pancreatic cancer	3.17e-05	0.000285	CcSEcCtD
Ponatinib—Visual impairment—Doxorubicin—pancreatic cancer	3.17e-05	0.000284	CcSEcCtD
Ponatinib—Alopecia—Epirubicin—pancreatic cancer	3.14e-05	0.000282	CcSEcCtD
Ponatinib—Nausea—Gemcitabine—pancreatic cancer	3.13e-05	0.000281	CcSEcCtD
Ponatinib—Mental disorder—Epirubicin—pancreatic cancer	3.11e-05	0.000279	CcSEcCtD
Ponatinib—Malnutrition—Epirubicin—pancreatic cancer	3.09e-05	0.000278	CcSEcCtD
Ponatinib—Erythema—Epirubicin—pancreatic cancer	3.09e-05	0.000278	CcSEcCtD
Ponatinib—Nausea—Fluorouracil—pancreatic cancer	3.08e-05	0.000276	CcSEcCtD
Ponatinib—Eye disorder—Doxorubicin—pancreatic cancer	3.07e-05	0.000276	CcSEcCtD
Ponatinib—Gastrointestinal pain—Docetaxel—pancreatic cancer	3.06e-05	0.000275	CcSEcCtD
Ponatinib—Cardiac disorder—Doxorubicin—pancreatic cancer	3.05e-05	0.000274	CcSEcCtD
Ponatinib—Flushing—Doxorubicin—pancreatic cancer	3.05e-05	0.000274	CcSEcCtD
Ponatinib—Back pain—Epirubicin—pancreatic cancer	2.99e-05	0.000268	CcSEcCtD
Ponatinib—Angiopathy—Doxorubicin—pancreatic cancer	2.98e-05	0.000268	CcSEcCtD
Ponatinib—Muscle spasms—Epirubicin—pancreatic cancer	2.97e-05	0.000267	CcSEcCtD
Ponatinib—Mediastinal disorder—Doxorubicin—pancreatic cancer	2.96e-05	0.000266	CcSEcCtD
Ponatinib—Abdominal pain—Docetaxel—pancreatic cancer	2.96e-05	0.000265	CcSEcCtD
Ponatinib—Body temperature increased—Docetaxel—pancreatic cancer	2.96e-05	0.000265	CcSEcCtD
Ponatinib—Chills—Doxorubicin—pancreatic cancer	2.95e-05	0.000265	CcSEcCtD
Ponatinib—Arrhythmia—Doxorubicin—pancreatic cancer	2.93e-05	0.000264	CcSEcCtD
Ponatinib—Vision blurred—Epirubicin—pancreatic cancer	2.91e-05	0.000262	CcSEcCtD
Ponatinib—Alopecia—Doxorubicin—pancreatic cancer	2.9e-05	0.000261	CcSEcCtD
Ponatinib—Mental disorder—Doxorubicin—pancreatic cancer	2.88e-05	0.000258	CcSEcCtD
Ponatinib—Erythema—Doxorubicin—pancreatic cancer	2.86e-05	0.000257	CcSEcCtD
Ponatinib—Malnutrition—Doxorubicin—pancreatic cancer	2.86e-05	0.000257	CcSEcCtD
Ponatinib—Anaemia—Epirubicin—pancreatic cancer	2.86e-05	0.000257	CcSEcCtD
Ponatinib—Leukopenia—Epirubicin—pancreatic cancer	2.77e-05	0.000248	CcSEcCtD
Ponatinib—Back pain—Doxorubicin—pancreatic cancer	2.77e-05	0.000248	CcSEcCtD
Ponatinib—Muscle spasms—Doxorubicin—pancreatic cancer	2.75e-05	0.000247	CcSEcCtD
Ponatinib—Cough—Epirubicin—pancreatic cancer	2.7e-05	0.000242	CcSEcCtD
Ponatinib—Vision blurred—Doxorubicin—pancreatic cancer	2.69e-05	0.000242	CcSEcCtD
Ponatinib—Asthenia—Docetaxel—pancreatic cancer	2.68e-05	0.000241	CcSEcCtD
Ponatinib—Hypertension—Epirubicin—pancreatic cancer	2.67e-05	0.00024	CcSEcCtD
Ponatinib—Pruritus—Docetaxel—pancreatic cancer	2.65e-05	0.000238	CcSEcCtD
Ponatinib—Anaemia—Doxorubicin—pancreatic cancer	2.64e-05	0.000237	CcSEcCtD
Ponatinib—Arthralgia—Epirubicin—pancreatic cancer	2.63e-05	0.000236	CcSEcCtD
Ponatinib—Myalgia—Epirubicin—pancreatic cancer	2.63e-05	0.000236	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	2.61e-05	0.000235	CcSEcCtD
Ponatinib—Dry mouth—Epirubicin—pancreatic cancer	2.57e-05	0.000231	CcSEcCtD
Ponatinib—Leukopenia—Doxorubicin—pancreatic cancer	2.56e-05	0.00023	CcSEcCtD
Ponatinib—Diarrhoea—Docetaxel—pancreatic cancer	2.56e-05	0.00023	CcSEcCtD
Ponatinib—Oedema—Epirubicin—pancreatic cancer	2.52e-05	0.000227	CcSEcCtD
Ponatinib—Infection—Epirubicin—pancreatic cancer	2.51e-05	0.000225	CcSEcCtD
Ponatinib—Cough—Doxorubicin—pancreatic cancer	2.49e-05	0.000224	CcSEcCtD
Ponatinib—Nervous system disorder—Epirubicin—pancreatic cancer	2.47e-05	0.000222	CcSEcCtD
Ponatinib—Dizziness—Docetaxel—pancreatic cancer	2.47e-05	0.000222	CcSEcCtD
Ponatinib—Thrombocytopenia—Epirubicin—pancreatic cancer	2.47e-05	0.000222	CcSEcCtD
Ponatinib—Hypertension—Doxorubicin—pancreatic cancer	2.47e-05	0.000222	CcSEcCtD
Ponatinib—Skin disorder—Epirubicin—pancreatic cancer	2.45e-05	0.00022	CcSEcCtD
Ponatinib—Hyperhidrosis—Epirubicin—pancreatic cancer	2.44e-05	0.000219	CcSEcCtD
Ponatinib—Myalgia—Doxorubicin—pancreatic cancer	2.43e-05	0.000219	CcSEcCtD
Ponatinib—Arthralgia—Doxorubicin—pancreatic cancer	2.43e-05	0.000219	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	2.42e-05	0.000217	CcSEcCtD
Ponatinib—Dry mouth—Doxorubicin—pancreatic cancer	2.38e-05	0.000214	CcSEcCtD
Ponatinib—Vomiting—Docetaxel—pancreatic cancer	2.38e-05	0.000214	CcSEcCtD
Ponatinib—Rash—Docetaxel—pancreatic cancer	2.36e-05	0.000212	CcSEcCtD
Ponatinib—Dermatitis—Docetaxel—pancreatic cancer	2.36e-05	0.000212	CcSEcCtD
Ponatinib—Headache—Docetaxel—pancreatic cancer	2.34e-05	0.00021	CcSEcCtD
Ponatinib—Oedema—Doxorubicin—pancreatic cancer	2.33e-05	0.00021	CcSEcCtD
Ponatinib—Infection—Doxorubicin—pancreatic cancer	2.32e-05	0.000208	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	2.3e-05	0.000206	CcSEcCtD
Ponatinib—Nervous system disorder—Doxorubicin—pancreatic cancer	2.29e-05	0.000206	CcSEcCtD
Ponatinib—Thrombocytopenia—Doxorubicin—pancreatic cancer	2.28e-05	0.000205	CcSEcCtD
Ponatinib—Insomnia—Epirubicin—pancreatic cancer	2.28e-05	0.000205	CcSEcCtD
Ponatinib—Skin disorder—Doxorubicin—pancreatic cancer	2.27e-05	0.000204	CcSEcCtD
Ponatinib—Paraesthesia—Epirubicin—pancreatic cancer	2.26e-05	0.000203	CcSEcCtD
Ponatinib—Hyperhidrosis—Doxorubicin—pancreatic cancer	2.26e-05	0.000203	CcSEcCtD
Ponatinib—Dyspnoea—Epirubicin—pancreatic cancer	2.25e-05	0.000202	CcSEcCtD
Ponatinib—Nausea—Docetaxel—pancreatic cancer	2.22e-05	0.000199	CcSEcCtD
Ponatinib—Dyspepsia—Epirubicin—pancreatic cancer	2.22e-05	0.000199	CcSEcCtD
Ponatinib—Decreased appetite—Epirubicin—pancreatic cancer	2.19e-05	0.000197	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Epirubicin—pancreatic cancer	2.18e-05	0.000196	CcSEcCtD
Ponatinib—Fatigue—Epirubicin—pancreatic cancer	2.17e-05	0.000195	CcSEcCtD
Ponatinib—Pain—Epirubicin—pancreatic cancer	2.16e-05	0.000194	CcSEcCtD
Ponatinib—Constipation—Epirubicin—pancreatic cancer	2.16e-05	0.000194	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	2.13e-05	0.000191	CcSEcCtD
Ponatinib—Insomnia—Doxorubicin—pancreatic cancer	2.11e-05	0.00019	CcSEcCtD
Ponatinib—Paraesthesia—Doxorubicin—pancreatic cancer	2.1e-05	0.000188	CcSEcCtD
Ponatinib—Dyspnoea—Doxorubicin—pancreatic cancer	2.08e-05	0.000187	CcSEcCtD
Ponatinib—Gastrointestinal pain—Epirubicin—pancreatic cancer	2.06e-05	0.000185	CcSEcCtD
Ponatinib—Dyspepsia—Doxorubicin—pancreatic cancer	2.05e-05	0.000184	CcSEcCtD
Ponatinib—Decreased appetite—Doxorubicin—pancreatic cancer	2.03e-05	0.000182	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	2.01e-05	0.000181	CcSEcCtD
Ponatinib—Fatigue—Doxorubicin—pancreatic cancer	2.01e-05	0.000181	CcSEcCtD
Ponatinib—Pain—Doxorubicin—pancreatic cancer	2e-05	0.000179	CcSEcCtD
Ponatinib—Constipation—Doxorubicin—pancreatic cancer	2e-05	0.000179	CcSEcCtD
Ponatinib—Abdominal pain—Epirubicin—pancreatic cancer	1.99e-05	0.000179	CcSEcCtD
Ponatinib—Body temperature increased—Epirubicin—pancreatic cancer	1.99e-05	0.000179	CcSEcCtD
Ponatinib—Gastrointestinal pain—Doxorubicin—pancreatic cancer	1.91e-05	0.000171	CcSEcCtD
Ponatinib—Abdominal pain—Doxorubicin—pancreatic cancer	1.84e-05	0.000166	CcSEcCtD
Ponatinib—Body temperature increased—Doxorubicin—pancreatic cancer	1.84e-05	0.000166	CcSEcCtD
Ponatinib—Asthenia—Epirubicin—pancreatic cancer	1.81e-05	0.000163	CcSEcCtD
Ponatinib—Pruritus—Epirubicin—pancreatic cancer	1.78e-05	0.00016	CcSEcCtD
Ponatinib—Diarrhoea—Epirubicin—pancreatic cancer	1.73e-05	0.000155	CcSEcCtD
Ponatinib—Asthenia—Doxorubicin—pancreatic cancer	1.67e-05	0.00015	CcSEcCtD
Ponatinib—Dizziness—Epirubicin—pancreatic cancer	1.67e-05	0.00015	CcSEcCtD
Ponatinib—Pruritus—Doxorubicin—pancreatic cancer	1.65e-05	0.000148	CcSEcCtD
Ponatinib—Vomiting—Epirubicin—pancreatic cancer	1.6e-05	0.000144	CcSEcCtD
Ponatinib—Diarrhoea—Doxorubicin—pancreatic cancer	1.6e-05	0.000143	CcSEcCtD
Ponatinib—Rash—Epirubicin—pancreatic cancer	1.59e-05	0.000143	CcSEcCtD
Ponatinib—Dermatitis—Epirubicin—pancreatic cancer	1.59e-05	0.000143	CcSEcCtD
Ponatinib—Headache—Epirubicin—pancreatic cancer	1.58e-05	0.000142	CcSEcCtD
Ponatinib—Dizziness—Doxorubicin—pancreatic cancer	1.54e-05	0.000139	CcSEcCtD
Ponatinib—Nausea—Epirubicin—pancreatic cancer	1.5e-05	0.000135	CcSEcCtD
Ponatinib—Vomiting—Doxorubicin—pancreatic cancer	1.48e-05	0.000133	CcSEcCtD
Ponatinib—Rash—Doxorubicin—pancreatic cancer	1.47e-05	0.000132	CcSEcCtD
Ponatinib—Dermatitis—Doxorubicin—pancreatic cancer	1.47e-05	0.000132	CcSEcCtD
Ponatinib—Headache—Doxorubicin—pancreatic cancer	1.46e-05	0.000131	CcSEcCtD
Ponatinib—Nausea—Doxorubicin—pancreatic cancer	1.39e-05	0.000124	CcSEcCtD
Ponatinib—FGFR1—Signaling Pathways—CCND1—pancreatic cancer	1.49e-06	1.5e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—SRC—pancreatic cancer	1.49e-06	1.5e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCND1—pancreatic cancer	1.49e-06	1.49e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PTEN—pancreatic cancer	1.48e-06	1.49e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CTNNB1—pancreatic cancer	1.48e-06	1.48e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CTNNB1—pancreatic cancer	1.48e-06	1.48e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GLP1R—pancreatic cancer	1.47e-06	1.48e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—STK11—pancreatic cancer	1.47e-06	1.47e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—HRAS—pancreatic cancer	1.47e-06	1.47e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PIK3CB—pancreatic cancer	1.47e-06	1.47e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CTNNB1—pancreatic cancer	1.46e-06	1.46e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—HRAS—pancreatic cancer	1.46e-06	1.46e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—PIK3CA—pancreatic cancer	1.45e-06	1.46e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—HRAS—pancreatic cancer	1.45e-06	1.46e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MMP9—pancreatic cancer	1.45e-06	1.45e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—DPYD—pancreatic cancer	1.45e-06	1.45e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—PIK3CA—pancreatic cancer	1.45e-06	1.45e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MMP9—pancreatic cancer	1.45e-06	1.45e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—APOE—pancreatic cancer	1.44e-06	1.45e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PTEN—pancreatic cancer	1.44e-06	1.45e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—HRAS—pancreatic cancer	1.44e-06	1.45e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—STAT3—pancreatic cancer	1.44e-06	1.44e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PTEN—pancreatic cancer	1.44e-06	1.44e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NFKBIA—pancreatic cancer	1.44e-06	1.44e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—NRAS—pancreatic cancer	1.43e-06	1.44e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—SRC—pancreatic cancer	1.43e-06	1.44e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—PTEN—pancreatic cancer	1.42e-06	1.43e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NOTCH1—pancreatic cancer	1.42e-06	1.43e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—HRAS—pancreatic cancer	1.42e-06	1.42e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CXCL8—pancreatic cancer	1.41e-06	1.41e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—SRC—pancreatic cancer	1.41e-06	1.41e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—AKT1—pancreatic cancer	1.41e-06	1.41e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—pancreatic cancer	1.4e-06	1.4e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CB—pancreatic cancer	1.39e-06	1.4e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CG—pancreatic cancer	1.39e-06	1.39e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—PIK3CA—pancreatic cancer	1.38e-06	1.39e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—STAT3—pancreatic cancer	1.38e-06	1.39e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—PIK3CA—pancreatic cancer	1.38e-06	1.39e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—pancreatic cancer	1.38e-06	1.38e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CD—pancreatic cancer	1.38e-06	1.38e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NRAS—pancreatic cancer	1.38e-06	1.38e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—AKT1—pancreatic cancer	1.38e-06	1.38e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—PIK3CA—pancreatic cancer	1.38e-06	1.38e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—SRC—pancreatic cancer	1.38e-06	1.38e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	1.38e-06	1.38e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGF—pancreatic cancer	1.37e-06	1.38e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—pancreatic cancer	1.37e-06	1.38e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—STAT3—pancreatic cancer	1.36e-06	1.36e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NRAS—pancreatic cancer	1.36e-06	1.36e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—AKT1—pancreatic cancer	1.35e-06	1.36e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—AKT1—pancreatic cancer	1.35e-06	1.36e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CASP3—pancreatic cancer	1.35e-06	1.35e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CTNNB1—pancreatic cancer	1.35e-06	1.35e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—HRAS—pancreatic cancer	1.34e-06	1.35e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—HRAS—pancreatic cancer	1.34e-06	1.34e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—TYMS—pancreatic cancer	1.34e-06	1.34e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—pancreatic cancer	1.34e-06	1.34e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—SRC—pancreatic cancer	1.34e-06	1.34e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—SRC—pancreatic cancer	1.33e-06	1.34e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—STAT3—pancreatic cancer	1.33e-06	1.33e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—NRAS—pancreatic cancer	1.32e-06	1.33e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTEN—pancreatic cancer	1.31e-06	1.32e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCND1—pancreatic cancer	1.31e-06	1.32e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—EGFR—pancreatic cancer	1.31e-06	1.31e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	1.3e-06	1.31e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—pancreatic cancer	1.3e-06	1.31e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CTNNB1—pancreatic cancer	1.3e-06	1.3e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—pancreatic cancer	1.3e-06	1.3e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AKT1—pancreatic cancer	1.3e-06	1.3e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—STAT3—pancreatic cancer	1.29e-06	1.29e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NRAS—pancreatic cancer	1.29e-06	1.29e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—STAT3—pancreatic cancer	1.29e-06	1.29e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PIK3CA—pancreatic cancer	1.29e-06	1.29e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MYC—pancreatic cancer	1.29e-06	1.29e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—AKT1—pancreatic cancer	1.29e-06	1.29e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NRAS—pancreatic cancer	1.28e-06	1.29e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TGFB1—pancreatic cancer	1.28e-06	1.29e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—AKT1—pancreatic cancer	1.28e-06	1.29e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—HRAS—pancreatic cancer	1.28e-06	1.28e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HRAS—pancreatic cancer	1.28e-06	1.28e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—pancreatic cancer	1.28e-06	1.28e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HRAS—pancreatic cancer	1.27e-06	1.28e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—STAT3—pancreatic cancer	1.27e-06	1.28e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—AKT1—pancreatic cancer	1.27e-06	1.28e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—NRAS—pancreatic cancer	1.27e-06	1.27e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PTEN—pancreatic cancer	1.27e-06	1.27e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TYMS—pancreatic cancer	1.26e-06	1.27e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—pancreatic cancer	1.26e-06	1.27e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TGFB1—pancreatic cancer	1.26e-06	1.26e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PPARG—pancreatic cancer	1.26e-06	1.26e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EGFR—pancreatic cancer	1.26e-06	1.26e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—APOE—pancreatic cancer	1.25e-06	1.25e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—AKT1—pancreatic cancer	1.25e-06	1.25e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EGFR—pancreatic cancer	1.24e-06	1.24e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—KRAS—pancreatic cancer	1.23e-06	1.24e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—pancreatic cancer	1.23e-06	1.24e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—TGFB1—pancreatic cancer	1.23e-06	1.23e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CD—pancreatic cancer	1.22e-06	1.23e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—EGFR—pancreatic cancer	1.21e-06	1.21e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTEN—pancreatic cancer	1.2e-06	1.21e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CB—pancreatic cancer	1.2e-06	1.21e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—pancreatic cancer	1.2e-06	1.2e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TGFB1—pancreatic cancer	1.2e-06	1.2e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—pancreatic cancer	1.2e-06	1.2e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TGFB1—pancreatic cancer	1.19e-06	1.2e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KRAS—pancreatic cancer	1.19e-06	1.19e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKT1—pancreatic cancer	1.19e-06	1.19e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	1.18e-06	1.19e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKT1—pancreatic cancer	1.18e-06	1.19e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SRC—pancreatic cancer	1.18e-06	1.18e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—STAT3—pancreatic cancer	1.18e-06	1.18e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NRAS—pancreatic cancer	1.17e-06	1.18e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EGFR—pancreatic cancer	1.17e-06	1.18e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EGFR—pancreatic cancer	1.17e-06	1.17e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KRAS—pancreatic cancer	1.17e-06	1.17e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—EGFR—pancreatic cancer	1.16e-06	1.16e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CXCL8—pancreatic cancer	1.16e-06	1.16e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	1.15e-06	1.15e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—pancreatic cancer	1.15e-06	1.15e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—KRAS—pancreatic cancer	1.14e-06	1.14e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—PIK3CA—pancreatic cancer	1.13e-06	1.14e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—STAT3—pancreatic cancer	1.13e-06	1.14e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NRAS—pancreatic cancer	1.13e-06	1.13e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—AKT1—pancreatic cancer	1.13e-06	1.13e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKT1—pancreatic cancer	1.13e-06	1.13e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CG—pancreatic cancer	1.13e-06	1.13e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—AKT1—pancreatic cancer	1.13e-06	1.13e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KRAS—pancreatic cancer	1.11e-06	1.11e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CASP3—pancreatic cancer	1.11e-06	1.11e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KRAS—pancreatic cancer	1.1e-06	1.11e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—KRAS—pancreatic cancer	1.09e-06	1.1e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—pancreatic cancer	1.09e-06	1.1e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PIK3CA—pancreatic cancer	1.09e-06	1.09e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APOE—pancreatic cancer	1.09e-06	1.09e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—TGFB1—pancreatic cancer	1.09e-06	1.09e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPARG—pancreatic cancer	1.09e-06	1.09e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCND1—pancreatic cancer	1.08e-06	1.08e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PIK3CA—pancreatic cancer	1.07e-06	1.07e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—EGFR—pancreatic cancer	1.07e-06	1.07e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CTNNB1—pancreatic cancer	1.07e-06	1.07e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CB—pancreatic cancer	1.07e-06	1.07e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CD44—pancreatic cancer	1.06e-06	1.07e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—pancreatic cancer	1.06e-06	1.06e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—pancreatic cancer	1.05e-06	1.06e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TGFB1—pancreatic cancer	1.05e-06	1.05e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AKT1—pancreatic cancer	1.05e-06	1.05e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—HRAS—pancreatic cancer	1.05e-06	1.05e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PIK3CA—pancreatic cancer	1.05e-06	1.05e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—pancreatic cancer	1.05e-06	1.05e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PTEN—pancreatic cancer	1.04e-06	1.04e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—pancreatic cancer	1.04e-06	1.04e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EGFR—pancreatic cancer	1.03e-06	1.03e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APOE—pancreatic cancer	1.03e-06	1.03e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CXCL8—pancreatic cancer	1.02e-06	1.03e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GCG—pancreatic cancer	1.02e-06	1.02e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PIK3CA—pancreatic cancer	1.02e-06	1.02e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PIK3CA—pancreatic cancer	1.01e-06	1.02e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRAS—pancreatic cancer	1.01e-06	1.01e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—KRAS—pancreatic cancer	1.01e-06	1.01e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—PIK3CA—pancreatic cancer	1e-06	1.01e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	9.99e-07	1e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CD—pancreatic cancer	9.93e-07	9.95e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRAS—pancreatic cancer	9.92e-07	9.94e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—pancreatic cancer	9.9e-07	9.92e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—pancreatic cancer	9.84e-07	9.87e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CG—pancreatic cancer	9.84e-07	9.86e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—pancreatic cancer	9.82e-07	9.84e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CASP3—pancreatic cancer	9.8e-07	9.82e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KRAS—pancreatic cancer	9.74e-07	9.77e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—HRAS—pancreatic cancer	9.69e-07	9.72e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SRC—pancreatic cancer	9.64e-07	9.67e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—STK11—pancreatic cancer	9.6e-07	9.62e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCND1—pancreatic cancer	9.54e-07	9.56e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARG—pancreatic cancer	9.49e-07	9.52e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CTNNB1—pancreatic cancer	9.44e-07	9.47e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRAS—pancreatic cancer	9.41e-07	9.44e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—pancreatic cancer	9.39e-07	9.42e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRAS—pancreatic cancer	9.39e-07	9.41e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—STAT3—pancreatic cancer	9.3e-07	9.32e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—HRAS—pancreatic cancer	9.29e-07	9.32e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NRAS—pancreatic cancer	9.28e-07	9.3e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—PIK3CA—pancreatic cancer	9.27e-07	9.3e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	9.27e-07	9.29e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT1—pancreatic cancer	9.27e-07	9.29e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—pancreatic cancer	9.26e-07	9.28e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTEN—pancreatic cancer	9.21e-07	9.23e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PIK3CA—pancreatic cancer	8.95e-07	8.97e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARG—pancreatic cancer	8.95e-07	8.97e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT1—pancreatic cancer	8.92e-07	8.94e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT1—pancreatic cancer	8.76e-07	8.78e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—pancreatic cancer	8.66e-07	8.68e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CB—pancreatic cancer	8.65e-07	8.67e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CD—pancreatic cancer	8.65e-07	8.67e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—pancreatic cancer	8.64e-07	8.66e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTEN—pancreatic cancer	8.63e-07	8.65e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TGFB1—pancreatic cancer	8.62e-07	8.64e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—HRAS—pancreatic cancer	8.58e-07	8.6e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—pancreatic cancer	8.57e-07	8.59e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT1—pancreatic cancer	8.56e-07	8.58e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CA—pancreatic cancer	8.5e-07	8.52e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGFR—pancreatic cancer	8.45e-07	8.47e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—pancreatic cancer	8.31e-07	8.34e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT1—pancreatic cancer	8.31e-07	8.33e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT1—pancreatic cancer	8.29e-07	8.31e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRAS—pancreatic cancer	8.28e-07	8.3e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TYMS—pancreatic cancer	8.26e-07	8.28e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—STAT3—pancreatic cancer	8.23e-07	8.25e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NRAS—pancreatic cancer	8.21e-07	8.23e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT1—pancreatic cancer	8.21e-07	8.23e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	8.15e-07	8.17e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KRAS—pancreatic cancer	7.98e-07	8e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—pancreatic cancer	7.65e-07	7.67e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TGFB1—pancreatic cancer	7.63e-07	7.65e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT1—pancreatic cancer	7.58e-07	7.6e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CB—pancreatic cancer	7.54e-07	7.56e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGFR—pancreatic cancer	7.48e-07	7.5e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTEN—pancreatic cancer	7.48e-07	7.5e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—pancreatic cancer	7.47e-07	7.49e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CA—pancreatic cancer	7.34e-07	7.35e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT1—pancreatic cancer	7.31e-07	7.33e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	7.1e-07	7.12e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—pancreatic cancer	7.1e-07	7.11e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KRAS—pancreatic cancer	7.07e-07	7.09e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—pancreatic cancer	7.04e-07	7.06e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AKT1—pancreatic cancer	6.94e-07	6.96e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRAS—pancreatic cancer	6.79e-07	6.8e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOE—pancreatic cancer	6.72e-07	6.73e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTEN—pancreatic cancer	6.51e-07	6.53e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CA—pancreatic cancer	6.49e-07	6.51e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—pancreatic cancer	6.28e-07	6.3e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTEN—pancreatic cancer	6.14e-07	6.15e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	6.09e-07	6.1e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	6.06e-07	6.08e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRAS—pancreatic cancer	6.01e-07	6.02e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT1—pancreatic cancer	5.99e-07	6.01e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARG—pancreatic cancer	5.85e-07	5.86e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	5.33e-07	5.34e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT1—pancreatic cancer	5.31e-07	5.32e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CA—pancreatic cancer	5.27e-07	5.29e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKT1—pancreatic cancer	4.97e-07	4.99e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	4.64e-07	4.66e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—pancreatic cancer	4.6e-07	4.61e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CA—pancreatic cancer	4.59e-07	4.61e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	4.33e-07	4.34e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKT1—pancreatic cancer	4.31e-07	4.32e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTEN—pancreatic cancer	4.01e-07	4.02e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKT1—pancreatic cancer	3.75e-07	3.76e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKT1—pancreatic cancer	3.54e-07	3.55e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	2.83e-07	2.84e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKT1—pancreatic cancer	2.31e-07	2.32e-06	CbGpPWpGaD
